Health Canada monitors emerging COVID-19 variants detected in multiple countries

Public health authorities are closely observing a novel COVID-19 variant that has surfaced in various nations, as confirmed by officials. The World Health Organization (WHO) has designated the variant as BA.2.86, incorporating it into its monitored COVID-19 variants as of Thursday.

Global Monitoring Amidst Absence of Local Cases: Although no instances of the BA.2.86 variant have been verified within Canadian borders, Health Canada has asserted its commitment to vigilant oversight. In response to inquiries, Health Canada conveyed that its robust surveillance initiative, in collaboration with provincial and territorial entities, remains poised to identify any occurrences of this variant. A representative from Health Canada disclosed, "The Government of Canada has established a robust monitoring mechanism in coordination with provinces and territories to identify instances of COVID-19 variants in Canada." This assurance was furnished in an email statement on Monday.

Scientific Evaluation and Global Cooperation: Scientists from the Public Health Agency of Canada (PHAC) have joined forces with national and international experts to actively scrutinize and assess the BA.2.86 lineage and its associated studies. Despite its recent appearance, this variant has been detected in Denmark, Israel, and the United States since late July, as documented by the Global Initiative on Sharing All Influenza Data (GISAID), a comprehensive global genome sequencing database.

Caution Amidst the Emergence: Epidemiologists and specialists in infectious diseases are urging careful consideration in response to the emergence of the BA.2.86 variant. Dr. Isaac Bogoch, a distinguished contagious disease expert in Toronto, emphasized avoiding hasty conclusions. Dr. Bogoch stated, "We are observing six genotypes from four nations spread across three continents. That's the extent of our knowledge." He emphasized that the genetic composition of this variant contains noteworthy elements from both earlier BA2 and Delta mutations.

Transmissibility and Impact Uncertainties: Dr. Bogoch emphasized the preliminary nature of information regarding the transmissibility and impact of the BA.2.86 variant. He highlighted the significance of tactics like wastewater surveillance in detecting such mutations early and stressed that more data is required to understand its potential implications.

Situation Awareness and Global Data Sharing: Dr. Tyson Graber, a research associate at the CHEO Research Institute in Ottawa, underscored the evolving nature of the situation. He noted that while BA.2.86 hasn't contributed to the current wave of infections in various regions, but the surveillance networks provide valuable insights for the upcoming pandemic. Monitoring wastewater and clinical data remains an effective way to gain situational awareness.

Understanding Variants' Evolution: As the WHO explains, viruses, including SARS-CoV-2, responsible for COVID-19, naturally change over time. Most of these changes are inconsequential, but some may impact the virus's properties, affecting its spread, disease severity, vaccine efficacy, and more.

Anticipating the Future: Dr. Bogoch stressed the significance of early detection and global information sharing. He expressed optimism that more insights will be gained as additional genomes are analyzed. The uncertainty surrounding the potential impact of the BA.2.86 variant underscores the need for continued scientific scrutiny and collaborative international efforts.

-